Dylann Cohn-Emery | Authors

Targeting CD117 With JSP191, TBI, and Fludarabine Appears Safe and Efficacious in MDS/AML

April 29, 2022

JSP191 plus fludarabine and low-dose total body radiation to target CD117 was a safe strategy to induce facilitation of full donor myeloid chimerism and clear minimal residual disease in older patients with myelodysplastic syndrome and acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.

More Favorable Safety Profile of Acalabrutinib Vs Ibrutinib Validated for CLL

December 14, 2021

A post-hoc analysis of a phase 3 trial presented at 2021 ASH indicate that acalabrutinib may be favorable in terms of toxic burden and cardiovascular-related events when compared against ibrutinib for treating chronic lymphocytic leukemia.